| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/02/2002 | EP1200081A1 Treatment of neurotic disorders |
| 05/02/2002 | EP1200080A1 Assay for d-serine transport antagonist and use for treating psychosis |
| 05/02/2002 | EP1200079A2 2-aminotetralin derivatives for the therapy of glaucoma |
| 05/02/2002 | EP1200078A1 Compositions and methods for promoting nerve regeneration |
| 05/02/2002 | EP1200077A2 L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases |
| 05/02/2002 | EP1200076A1 Calcilytic compounds |
| 05/02/2002 | EP1200074A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 05/02/2002 | EP1200073A2 SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 05/02/2002 | EP1200072A2 Method of treating psychotic disorders |
| 05/02/2002 | EP1200070A1 Ambroxol-containing lozenge |
| 05/02/2002 | EP1200068A2 Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| 05/02/2002 | EP1200067A1 Delivery system for biological material |
| 05/02/2002 | EP1200066A1 Aqueous nasal formulation |
| 05/02/2002 | EP1200065A1 Intravaginal clindamycin ovule composition |
| 05/02/2002 | EP1200064A1 Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip |
| 05/02/2002 | EP1200063A1 Treatment and composition for achieving skin anti-aging benefits by corneum protease activation |
| 05/02/2002 | EP1200057A1 Colloidal composition for esthetic correction |
| 05/02/2002 | EP1200041A1 Sunscreen for the scalp and hair |
| 05/02/2002 | EP1200040A1 Two-component composition for cosmetic or pharmaceutical use |
| 05/02/2002 | EP1156791A4 Bupropion to treat viral diseases |
| 05/02/2002 | EP1146875A4 Myt1 kinase inhibitors |
| 05/02/2002 | EP1128835A4 Cyanocobalamin (vitamin b 12?) treatment in allergic disease |
| 05/02/2002 | EP1089726B1 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 05/02/2002 | EP1089720B1 Transdermal therapeutic system containing hormones and crystallization inhibitors |
| 05/02/2002 | EP1087748B1 Method of making antiperspirant powders |
| 05/02/2002 | EP1076718B1 Novel method for preparing synthesis intermediates |
| 05/02/2002 | EP1032376B1 Use of sulphinyl benzhydryl derivatives for treating drug-induced sleepiness |
| 05/02/2002 | EP1021189B1 Desferri-exochelin for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation |
| 05/02/2002 | EP0975216A4 A method for treating papillomavirus infections |
| 05/02/2002 | EP0946579B1 Novel erythromycin derivatives, method for preparing them and their use as medicine |
| 05/02/2002 | EP0941097B1 Use of mixtures of active substances for the production of hypocholesteremic agents |
| 05/02/2002 | EP0931086B1 Tetrahydronaphthalene derivatives and their therapeutic use |
| 05/02/2002 | EP0928192B1 Antimycotic gel with high active substance release |
| 05/02/2002 | EP0918758B1 Process for preparing 1-substituted 4-cyano-1,2,3-triazoles |
| 05/02/2002 | EP0918518A4 Treatment of mood/affective disorders by glutamatergic upmodulators |
| 05/02/2002 | EP0904031A4 Cationic polymer/lipid nucleic acid delivery vehicles |
| 05/02/2002 | EP0890359B1 Tablets containing beta-lactam antibiotic and process for producing the same |
| 05/02/2002 | EP0885004B1 Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers |
| 05/02/2002 | EP0881896B1 Skin treatment with salicylic acid esters and retinoids |
| 05/02/2002 | EP0879056B1 Modulation of th1/th2 cytokine expression by ribavirin in activated t-lymphocytes |
| 05/02/2002 | EP0846118B1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0840740B1 New inhibitors of platelet aggregation |
| 05/02/2002 | EP0833628A4 Novel taxoids |
| 05/02/2002 | EP0814784B1 USE OF NSAIDs FOR TREATMENT OF SQUAMOUS CELL CARCINOMAS OF THE ORAL CAVITY OR OROPHARYNX |
| 05/02/2002 | EP0812838B1 Pyridonecarboxylic acid derivative substituted by bicyclic amino group, ester thereof, salt thereof, and bicyclic amine as intermediate therefor |
| 05/02/2002 | EP0804199B1 Use of penciclovir for the treatment of post herpetic neuralgia |
| 05/02/2002 | EP0772442B1 Use of immunosuppressive agents for the treatment of schizophrenia |
| 05/02/2002 | EP0765336B1 Synthesis of conduritol epoxides and aziridines and methods of using such to synthesize higher disaccharides |
| 05/02/2002 | EP0725643B1 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
| 05/02/2002 | EP0615448B1 Sex steroid activity inhibitors |
| 05/02/2002 | EP0607164B1 Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists |
| 05/02/2002 | EP0561883B1 Polymorphs of crystalline mupirocin |
| 05/02/2002 | DE10140029A1 Vefahren zur Herstellung von Citalopram Vefahren for the preparation of citalopram |
| 05/02/2002 | DE10053397A1 Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases |
| 05/02/2002 | DE10052658A1 Neue Pyranosidderivate New Pyranosidderivate |
| 05/02/2002 | DE10052590A1 Verwendung von 2-Hydrazino-1,3-thiazolen als Antioxidantien Use of 2-hydrazino-1,3-thiazoles as antioxidants |
| 05/02/2002 | DE10052375A1 Reducing cholesterol levels in body fluids and tissues e.g. human blood, by administration of pentaerythritol mono-, di-, tri- or tetranitrate |
| 05/02/2002 | DE10052333A1 Neue Sulfooxybenzamide New Sulfooxybenzamide |
| 05/02/2002 | DE10052322A1 Storage-stable solid chlorhexidine composition used for preparing aqueous disinfectant solutions e.g. for skin disinfection contains sugar acid and microbicidal quaternary ammonium bromide |
| 05/02/2002 | DE10051609A1 Use of an inhibitor of the progesterone receptor for the production of an agent for the inhibition of the binding of growth factors to tumor cells or to a tumor |
| 05/02/2002 | DE10049549A1 Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40 |
| 05/02/2002 | DE10049484A1 Anticonvulsant, anxiolytic and especially analgesic medicaments, comprising new or known beta-thio-alpha-aminoacid compounds having strong affinity for gabapentin binding site |
| 05/02/2002 | DE10049483A1 Substituierte 1-Aminobutan-3-ol-Derivate Substituted 1-aminobutan-3-ol derivatives |
| 05/02/2002 | DE10049481A1 Substituierte C-Cyclohexylmethylamin-Derivate C-substituted derivatives cyclohexylmethylamine |
| 05/02/2002 | DE10038364A1 Pharmazeutische, Ramipril enthaltende Brauseformulierung Pharmaceutical, ramipril containing effervescent formulation |
| 05/02/2002 | CA2689012A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2678256A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2464228A1 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | CA2428907A1 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | CA2427068A1 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 05/02/2002 | CA2426898A1 A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| 05/02/2002 | CA2426896A1 Compositions and methods for the discovery and selection of biological information |
| 05/02/2002 | CA2426895A1 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 05/02/2002 | CA2426773A1 Beta-substituted beta-aminoethyl phosphonates |
| 05/02/2002 | CA2426741A1 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis |
| 05/02/2002 | CA2426706A1 Benzoxazinone derivatives, their preparation and use |
| 05/02/2002 | CA2426674A1 Agent for preventing or treating portal hypertension |
| 05/02/2002 | CA2426616A1 Polysubstituted imidazopyridines as gastric secretion inhibitors |
| 05/02/2002 | CA2426564A1 Pyranoside derivatives |
| 05/02/2002 | CA2426430A1 Biaryl compounds as serine protease inhibitors |
| 05/02/2002 | CA2426360A1 Enhancers for microbiological disinfection and targeted apoptosis |
| 05/02/2002 | CA2426244A1 Lipid formulations for target delivery |
| 05/02/2002 | CA2426218A1 Compositions for improving lipid content in the blood |
| 05/02/2002 | CA2426203A1 Anticancer agents based on regulation of protein prenylation |
| 05/02/2002 | CA2426007A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 05/02/2002 | CA2425908A1 Mammalian metabolites of a tachykinin receptor antagonist |
| 05/02/2002 | CA2425596A1 Methods of therapy for hiv infection |
| 05/02/2002 | CA2425288A1 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | CA2425283A1 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2425280A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | CA2424475A1 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | CA2422901A1 Use of tolterodine to treat asthma |
| 05/02/2002 | CA2422900A1 New composition and method for the treatment of dysglucaemia |
| 05/02/2002 | CA2422787A1 C-nitroso compounds and use thereof |
| 05/02/2002 | CA2421885A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | CA2420727A1 Triazole derivatives and pharmaceutical compositions comprising them |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | CA2419373A1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 05/02/2002 | CA2326004A1 Methods for treating cellular proliferative disorders |